Gary S. Leiserowitz

Oncology | Obstetrics and Gynecology

999 S Fairmont Ave
Ste 230
Lodi, CA 95240

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

A small pilot trial of virtual group cognitive behavioral therapy for insomnia in gynecologic oncology patients.

A small pilot trial of virtual group cognitive behavioral therapy for insomnia in gynecologic oncology patients.

Journal: Gynecologic oncology reports

Published: May 07, 2026

Unbiased assessment of APR-246 responsive p53 mutants in ovarian cancer.

Unbiased assessment of APR-246 responsive p53 mutants in ovarian cancer.

Journal: Cell death discovery

Published: November 12, 2025

BET inhibition disrupts the FOXM1-MYC axis to induce BRCAness and enhance PARP inhibitor response.

BET inhibition disrupts the FOXM1-MYC axis to induce BRCAness and enhance PARP inhibitor response.

Journal: NPJ precision oncology

Published: July 15, 2025

Patient Attitudes Toward Ambient Voice Technology: Preimplementation Patient Survey in an Academic Medical Center.

Patient Attitudes Toward Ambient Voice Technology: Preimplementation Patient Survey in an Academic Medical Center.

Journal: JMIR medical informatics

Published: May 23, 2025

NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.

NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: October 16, 2024

Integration of label-free surface enhanced Raman spectroscopy (SERS) of extracellular vesicles (EVs) with Raman tagged labels to enhance ovarian cancer diagnostics.

Integration of label-free surface enhanced Raman spectroscopy (SERS) of extracellular vesicles (EVs) with Raman tagged labels to enhance ovarian cancer diagnostics.

Journal: Biosensors & bioelectronics

Published: September 22, 2024

Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy.

Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy.

Journal: Nature communications

Published: July 05, 2024

Perspectives of gynecologic oncology fellowship training and preparedness for practice.

Perspectives of gynecologic oncology fellowship training and preparedness for practice.

Journal: Gynecologic oncology reports

Published: October 31, 2023

Documentation of Infertility Risk Discussion in Cancer Patients Receiving Cancer-Directed Therapy: The UC Davis Cancer Center Experience.

Documentation of Infertility Risk Discussion in Cancer Patients Receiving Cancer-Directed Therapy: The UC Davis Cancer Center Experience.

Journal: Journal of adolescent and young adult oncology

Published: August 23, 2023

Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer.

Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer.

Journal: Cell death and differentiation

Published: May 24, 2023

Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.

Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.

Journal: Gynecologic oncology

Published: March 25, 2023

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: September 08, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026